Gliflozins are inhibitors of sodium-glucose cotransporter 2 (SGLT2), which is responsible for reabsorption of >90% of glucose from primary urine, as shown in mice,251 and are widely approved for treating T2DM patients.214. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.